Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
About this item
Full title
Author / Creator
Levin, Myron J. , Ustianowski, Andrew , De Wit, Stéphane , Launay, Odile , Avila, Miles , Templeton, Alison , Yuan, Yuan , Seegobin, Seth , Ellery, Adam , Levinson, Dennis J. , Ambery, Philip , Arends, Rosalinda H. , Beavon, Rohini , Dey, Kanika , Garbes, Pedro , Kelly, Elizabeth J. , Koh, Gavin C.K.W. , Near, Karen A. , Padilla, Kelly W. , Psachoulia, Konstantina , Sharbaugh, Audrey , Streicher, Katie , Pangalos, Menelas N. , Esser, Mark T. and PROVENT Study Group
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
This randomized, controlled trial evaluated AZD7442 (a combination of tixagevimab and cilgavimab, monoclonal antibodies targeting the SARS-CoV-2 spike protein) for the prevention of Covid-19 in adults at high risk for SARS-CoV-2 infection. AZD7442 was found to have approximately 77% efficacy in preventing symptomatic infection.
Alternative Titles
Full title
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Authors, Artists and Contributors
Author / Creator
Ustianowski, Andrew
De Wit, Stéphane
Launay, Odile
Avila, Miles
Templeton, Alison
Yuan, Yuan
Seegobin, Seth
Ellery, Adam
Levinson, Dennis J.
Ambery, Philip
Arends, Rosalinda H.
Beavon, Rohini
Dey, Kanika
Garbes, Pedro
Kelly, Elizabeth J.
Koh, Gavin C.K.W.
Near, Karen A.
Padilla, Kelly W.
Psachoulia, Konstantina
Sharbaugh, Audrey
Streicher, Katie
Pangalos, Menelas N.
Esser, Mark T.
PROVENT Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2653269220
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2653269220
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2116620
